---
title: "VK2735 in Chronic weight management: Pharmacodynamics"
description: "Formulary evidence on VK2735 in Chronic weight management: Pharmacodynamics. Topics: Preclinical pharmacology of the dual agonist series: diet-induced obese mice compared with semaglutide, Preclinical pharmacology of the dual agonist series: diet-induced obese mice compared with tirzepatide, Preclinical pharmacology: 8-week weight change in obese primates compared with tirzepatide, Subcutaneous formulation: liver fat after four weekly doses in the phase 1 multiple ascending dose study, and 7 further topics. 11 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Preclinical pharmacology of the dual agonist series: diet-induced obese mice compared with semaglutide

> “Treatment with Viking dual agonists resulted in mean reductions in body weight of up to 27% relative to vehicle (p<0.0001), compared with a mean reduction of 18% among semaglutide-treated animals (p<0.0001 vs. semaglutide)”
> “Treatment with Viking dual agonists resulted in mean reductions in blood glucose of up to 23% relative to vehicle (p<0.0001), compared with a mean reduction of 7% among semaglutide-treated animals (p<0.0001 vs. semaglutide)”

Source: [Viking Therapeutics ObesityWeek 2021 preclinical release (2021)](https://ir.vikingtherapeutics.com/2021-11-01-Viking-Therapeutics-Presents-Preclinical-Data-on-Novel-Dual-GLP-1-GIP-Agonists-at-ObesityWeek-R-2021)

<a id="topic-2.1.2.6.2-2"></a>

### Preclinical pharmacology of the dual agonist series: diet-induced obese mice compared with tirzepatide

> “Treatment with Viking dual agonists resulted in mean reductions in body weight of up to 28% (p<0.0001 vs. vehicle) and reductions in plasma glucose of up to 26% (p<0.0001 vs. vehicle). These effects were comparable to those observed among tirzepatide-treated animals (29% and 25% reductions, respectively, vs. vehicle)”
> “Treatment with Viking dual agonists resulted in mean reductions in liver triglycerides of up to 49% relative to vehicle (p=0.01), compared with a 19% mean reduction among tirzepatide-treated animals (p<0.05 vs. tirzepatide)”

Source: [Viking Therapeutics ObesityWeek 2021 preclinical release (2021)](https://ir.vikingtherapeutics.com/2021-11-01-Viking-Therapeutics-Presents-Preclinical-Data-on-Novel-Dual-GLP-1-GIP-Agonists-at-ObesityWeek-R-2021)

<a id="topic-2.1.2.6.2-3"></a>

### Preclinical pharmacology: 8-week weight change in obese primates compared with tirzepatide

> “Significant, progressive body weight reduction observed over 8 weeks”
> “~40%+ improvement in weight loss vs. comparator at same doses”
> “Aligns with improved exposures at same dose levels”

Source: [Viking Therapeutics corporate presentation (2026)](https://ir.vikingtherapeutics.com/download/Viking+Therapeutics+Corporate+Presentation+November+2026.pdf)

<a id="topic-2.1.2.6.2-4"></a>

### Subcutaneous formulation: liver fat after four weekly doses in the phase 1 multiple ascending dose study

> “Following 28 days of once-weekly treatment with VK2735, study results demonstrated reductions in liver fat content, both as compared to baseline and as compared to placebo. Subjects receiving VK2735 experienced reductions in liver fat ranging up to 47.2% from baseline.”
> “In the subgroup of study subjects with non-alcoholic fatty liver disease (NAFLD), defined as those with greater than 5% liver fat at baseline, the reductions in liver fat levels were more pronounced. For these subjects, reductions from baseline after four weekly doses ranged up to 49.7%, and placebo-adjusted reductions of up to 58.5% were reported.”

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="topic-2.1.2.6.2-5"></a>

### Subcutaneous formulation: plasma lipids in the phase 1 multiple ascending dose study

> “Dose dependent reductions from baseline in these plasma lipid levels were observed across VK2735 treatment cohorts after four weekly doses. No meaningful changes in levels of high-density lipoprotein cholesterol (HDL-C) were observed following treatment with VK2735.”

Source: [Viking Therapeutics ObesityWeek 2023 release (2023)](https://ir.vikingtherapeutics.com/2023-10-17-Viking-Therapeutics-Presents-New-Data-from-Phase-1-Clinical-Trial-of-Dual-GLP-1-GIP-Receptor-Agonist-VK2735-in-Oral-Presentation-at-ObesityWeek-2023)

<a id="topic-2.1.2.6.2-6"></a>

### Subcutaneous formulation: glycemic status and lipids at week 13 in the phase 2 trial

> “Of the 74 participants who had prediabetes at baseline, 58 (78%) shifted to normoglycemic at Week 13 in the active treatment groups and none shifted from prediabetes to diabetes.”
> “Lipid markers generally declined over the 13‐week study in the active treatment group”
> “Only total cholesterol had a p value less than 0.05 versus placebo”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.6.2-7"></a>

### Subcutaneous formulation: fasting glucose, HbA1c, and blood pressure at week 13 in the phase 2 trial

| Measure, change from baseline (LS mean (SE)) | Placebo | 2.5 mg | 5.0 mg | 10 mg | 15 mg |
| --- | --- | --- | --- | --- | --- |
| Glucose, mg/dL | “−0.37 (1.475)” | “−10.66 (1.439)” | “−10.23 (1.424)” | “−9.46 (1.424)” | “−10.85 (1.456)” |
| Hemoglobin A1c, % | “0.03 (0.041)” | “−0.29 (0.040)” | “−0.27 (0.040)” | “−0.27 (0.039)” | “−0.36 (0.040)” |
| Systolic blood pressure, mmHg | “−4.20 (1.993)” | “−6.87 (1.906)” | “−6.71 (1.931)” | “−7.04 (1.936)” | “−10.97 (2.000)” |
| Diastolic blood pressure, mmHg | “−1.68 (1.286)” | “−3.27 (1.229)” | “−4.34 (1.246)” | “−2.37 (1.247)” | “−5.16 (1.290)” |

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.6.2-8"></a>

### Subcutaneous formulation: weight loss persisting after the last dose in the phase 2 trial

> “>90% of weight reduction maintained 4 weeks post-final dose”

Source: [Alkhouri et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/Results-From-the-13-Week-VENTURE-Phase-2a-Study-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Obese-Patients.pdf)

<a id="topic-2.1.2.6.2-9"></a>

### Subcutaneous formulation: maximal effect not reached in 13 weeks

> “Maximal therapeutic levels were likely not yet achieved in this limited duration study.”

Source: [Bays et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12933218/)

<a id="topic-2.1.2.6.2-10"></a>

### Oral formulation: satiety and appetite in the phase 1 multiple ascending dose study

> “Majority of subjects dosed ≥40 mg reported reduced appetite/increased satiety, including all subjects in 100 mg cohort.”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-2.1.2.6.2-11"></a>

### Oral formulation: weight loss persisting after the last dose and with every-other-day dosing

> “Durable weight loss observed up to Day 57, 4 weeks after last dose of VK2735”
> “QD to QoD transition produces similar weight loss and trajectory; suggests reduced exposures may be effective in maintenance setting”

Source: [Neutel et al. (2024)](https://vikingtherapeutics.com/wp-content/uploads/2026/03/First-in-Human-Study-of-an-Oral-Formulation-of-the-GLP-1GIP-Co-Agonist-VK2735-in-Healthy-Adults.pdf)

<a id="topic-2.1.2.6.2-12"></a>

### Gastric emptying, energy intake, and body composition in humans

No evidence found.

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
